Page 25 - Linical Evolution News Today

June 2021 marks the 40th anniversary of the publication of the first reported cases of AIDS in the US. A session at BIO Digital – featuring Dr. Anthony Fauci, Director of NIAID at the NIH – will focus on four decades of innovation as well as the critical importance of collaboration and investment moving forward. On June 5, 1981, the Centers for Disease Control’s Morbidity and Mortality Weekly Report described 5 cases of  The UN wants to end the AIDS epidemic b...

BMS drug Opdivo lands FDA approval for gastro cancers By Jenni Spinner The therapeutic has been approved as an adjuvant treatment for varieties of esophageal cancers in patients who have received neoadjuvant chemoradiotherapy. Bristol Myers Squibb (BMS) announced the US Food and Drug Administration (FDAP has approved Opdivo (nivolumab, injection for intravenous use) for adjuvant treatment of completely resected esophageal o...

Despite COVID-19, pharma R&D funding at all-time high: IQVIA According to the clinical research solutions firm, disruptions due to the pandemic did not stop the industry from fueling R&D at unprecedented levels. The IQVIA Institute for Human Data Science has released its latest industry latest report, Global Trends in R&D: Overview Through 2020. According to the findings, research and development funding maintained historically high levels, thanks to new funding sour...

The trial services firm has entered an acquisition agreement with Thoma Bravo, a private equity company centered on software and technology services. Greenphire, a technology firm that provides financial lifecycle management solutions for clinical trials, has entered an agreement with Thoma Bravo, a private equity outfit that focuses on software and technology buys. The deal is expected to wrap in the second quarter of 2021, pending regulatory approvals; financial de...

The EMPHATHY clinical trial will enroll patients with COVID-19 to test the drug’s effectiveness in preventing worsening of symptoms and hospitalization. Novartis and Molecular Partners have announced the start of their EMPATHY Phase II/III study to explore the use of its DARPin (designed ankyrin repeat proteins) therapeutic candidate ensovibep (MP0420) for the treatment of COVID-19. Novartis reportedly will run the trial program, with Molecular Partners serving as ...

Created by an industry veteran with more than 20 years’ experience, Protodigm aims to offer innovation and expertise to pharmaceutical industry clients.

FDA leader discusses breaking barriers in clinical care Acting FDA commissioner Janet Woodcock explains how government, researchers, doctors and patients can contribute to improving the clinical research system. With more than three decades of experience at the US Food and Drug Administration (FDA), acting commissioner Janet Woodcock has an informed perspective of the government’s contributions to pharmaceutical development, drug safety, and clinical research. She�...

BBK Worldwide launches patient-centric trial resource With the Engagement Solution Center, the patient-recruitment services specialist is aiming to improve the patient-centricity and inclusivity of studies. BBK Worldwide has announced the creation of its Engagement Solution Center, a new resource designed to centralize design, management, operations, and communications of various patient-visit support services. The center is geared toward easing the burden of researc...

Starting studies right can ensure a stronger finish: Oracle A leader from the clinical trial technology firm suggests ways to design research from the start to help accelerate studies and avoid stumbling blocks. While clinical trials have made a number of advancements in decentralized design, data processing, and other aspects, one area remains a pervasive challenge: startup time. Outsourcing-Pharma recently spoke with Jae Chung, vice president of product management ...

Drug development advancements call for skilled workforce According to a leader from Saama Technologies, keeping competitive in the face of technology evolution requires staff that can keep up with the changes. Suresh Katta, CEO and founder of Saama Technologies, spoke with Outsourcing-Pharma about the rapid technological advancements in the drug development field, and how companies can cultivate a workforce capable of keeping up. OSP: Could you please talk about som...